Than et al. reported that stage II CRC patients whose cancers maintained high CFTR expression had a significantly better prognosis and disease free survival (DFS) than patients whose cancers demonstrated low CFTR expression [37]. This evidence concerns the gene CFTR and colorectal carcinoma.